newdrugapprovals.org
CHINA MARKET-Takeda and Sanofi Sign Co-promotion Agreement to Expand Reach of Diabetes Treatment Alogliptin in China
ALOGLIPTIN 22.04.2013 • Alogliptin is a DPP-4 inhibitor that is designed to slow the inactivation of incretin hormones GLP-1 and GIP • Agreement is part of Takeda’s strategy to complement capabilit…